Screener
ArriVent BioPharma, Inc. AVBP Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Total operating expenses | 46,111 | 66,772 |
| Operating loss | (46,111) | (66,772) |
| Interest and investment income | 2,791 | 2,385 |
| Net loss | (43,320) | (64,387) |
| Unrealized gain (loss) on marketable securities | (284) | 194 |
| Total other comprehensive gain (loss) | (284) | 194 |
| Total comprehensive loss | $(43,604) | $(64,193) |
| Share information: |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s business segments — net income loss?
- ArriVent BioPharma, Inc. (AVBP) reported business segments — net income loss of -$43.32M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s business segments — net income loss changed year-over-year?
- ArriVent BioPharma, Inc.'s business segments — net income loss increased by 32.7% year-over-year, from -$64.39M to -$43.32M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s business segments — net income loss?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s business segments — net income loss has grown at a 54.9% compound annual growth rate (CAGR), from -$69.33M to -$166.31M.
- What does business segments — net income loss mean?
- This metric represents the total profit or loss generated by the business segment after accounting for all revenues and operating expenses. For clinical-stage companies, this typically reflects the net burn rate as the firm invests heavily in drug development without significant commercial revenue. It is the primary indicator of the segment's overall financial health and sustainability.
Ask your AI about ArriVent BioPharma, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude